acetylleucyl-leucyl-norleucinal has been researched along with sja 6017 in 1 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (sja 6017) | Trials (sja 6017) | Recent Studies (post-2010) (sja 6017) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 25 | 0 | 4 |
| Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | sja 6017 (IC50) |
|---|---|---|---|
| Calpain-9 | Homo sapiens (human) | 2.23 | |
| Calpain-1 catalytic subunit | Homo sapiens (human) | 0.022 | |
| Calpain-1 catalytic subunit | Sus scrofa (pig) | 0.0212 | |
| Calpain-2 catalytic subunit | Sus scrofa (pig) | 0.078 | |
| Calpain-1 catalytic subunit | Rattus norvegicus (Norway rat) | 0.0075 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, SA; Banerjee, S; Gayen, S; Ghosh, K; Jha, T | 1 |
1 review(s) available for acetylleucyl-leucyl-norleucinal and sja 6017
| Article | Year |
|---|---|
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Molecular Docking Simulation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; SARS-CoV-2 | 2021 |